What’s New

Happy Holidays from MORSE Consulting! As we enter the festive season and the close of our seventh year of operations, we wish to express our heartfelt gratitude to the Pharmaceutical Market Access community, including our clients, strategic partners, and team members   In appreciation of your continued support, MORSE has made a donation to the Ottawa and Toronto Food Banks to help support families in need in these communities. We…

Toronto, ON – October 3, 2023 – MORSE Consulting is delighted to announce a formal collaboration with Ben Faienza, President and Principal of F5 Management Consulting, as a Strategic Advisor.  This collaboration represents a significant milestone for our firm, enhancing our market access capabilities. F5 Management Consulting, established in February 2023, provides strategic and operational guidance to bio-pharmaceutical companies entering the Canadian market.  With over 30 years of experience in…

September 14, 2023 - We are thrilled to announce a groundbreaking collaboration between MORSE Consulting and Medlior Health Outcomes Research, two leaders in the Canadian pharmaceutical market access landscape. This partnership aims to blend MORSE Consulting's unparalleled expertise in payer and HTA strategies with Medlior's cutting-edge real-world evidence solutions, offering our clients an unmatched array of services to navigate the complex world of pharmaceutical market access. MORSE Consulting is a…

Happy Holidays from MORSE Consulting! As we enter the festive season and close our sixth year of operations, we express our heartfelt gratitude to the pharmaceutical market access community, including our clients, strategic partners, and team members. We wish you all a safe, peaceful, and enjoyable holiday season and the best for 2023!!   —  

Toronto, September 7, 2022 – MORSE Consulting is delighted to announce the addition of 2 new team members, Jaclyn Beca and Sang Mi Lee who will enhance MORSE’s reimbursement expertise into pharmacoeconomics, generation and use of real world evidence (RWE) and development of innovative agreements. We are at an exciting time in drug discovery and research as new technologies, such as cell and gene therapies, offer opportunities to treat and…

Wishing you Season’s Greetings from MORSE Consulting! As we enter the holiday season and close our fifth year of operations, we would like to express our appreciation and gratitude to the pharmaceutical market access community, including our clients, strategic partners, and team members. We wish you all a safe, healthy, and enjoyable holiday break and the very best for 2022!   Happy Holidays,   —  

Toronto, September 7, 2021 – MORSE Consulting is pleased to announce the addition of Katherine Scott as a Consultant. The Canadian public system remains one of the critical payers in this country’s pharmaceutical reimbursement pathway. This system is growing increasingly complex with new funding mechanisms for emerging gene and cell therapies, novel approaches related to outcomes-based agreements, evolving policies related to biosimilars, and variations in how provincial payers implement pCPA…

  Happy Holidays from MORSE Consulting! As we enter the holiday season and the close of our fourth year of MORSE’s operations, we wish to share our gratitude to our community – our clients, strategic partners, and team members, for banding together and supporting each other through a challenging year.   —  

Toronto, September 9, 2020 – MORSE Consulting is pleased to announce that Sal Cimino has joined our team as Senior Consultant, Private Drug Plans. The private payer market is playing an increasingly important role in ensuring a product’s reimbursement success in Canada. With the introduction of new specialty biologics and gene therapies, private payers are turning to new cost containment strategies that strongly resemble the public payer market. Private payers…

Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns. Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system.  Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an issue for all stakeholders. To help…

  Happy Holidays from MORSE Consulting! As we enter the holiday season and the close of MORSE’s third year of operation, we wish to express our heartfelt gratitude to the Pharmaceutical Market Access community. We wish you a safe, peaceful, and enjoyable holiday season and the very best for 2020!   —